Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT · References

References

CC BY 4.0 · NIHR Journals Library · approximately 21 min read

  1. Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. Lancet 2018;392:2583–94.30466866
  2. Cancer Research UK. Cancer Statistics for the UK. London: Cancer Research UK. URL: www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk (accessed 31 October 2017).
  3. World Cancer Research Fund International. About Our Cancer Prevention Recommendations. What Are They and How Do They Reduce Cancer Risk? URL: www.wcrf.org/int/cancer-facts-figures/preventability-estimates/cancer-preventability-estimates-diet-nutrition (accessed 2 November 2017).
  4. Grady WM, Markowitz SD. The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci 2015;60:762–72. 10.1007/s10620-014-3444-425492499
  5. Strum WB. Colorectal adenomas. N Engl J Med 2016;374:1065–75. 10.1056/NEJMra151358126981936
  6. Cancer Research UK. Bowel Cancer Survival Statistics. London: Cancer Research UK. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival#ref-3 (accessed 2 November 2017).
  7. Office for National Statistics (ONS). Cancer Survival by Stage at Diagnosis for England (Experimental Statistics): Adults Diagnosed 2012, 2013 and 2014 and Followed Up to 2015. Newport: ONS; 2016. URL: www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalbystageatdiagnosisforenglandexperimentalstatistics/adultsdiagnosed20122013and2014andfollowedupto2015 (accessed 2 November 2017).
  8. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095–105. 10.1056/NEJMoa130196924047059
  9. Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687–96. 10.1056/NEJMoa110037022356322
  10. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624–33. 10.1016/S0140-6736(10)60551-X20430429
  11. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1–8. 10.7326/0003-4819-150-1-200901060-0030619075198
  12. Hoff G, Grotmol T, Skovlund E, Brett Hauer M, Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009;338:b1846. 10.1136/bmj.b184619483252
  13. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603–7. 10.1056/NEJM20001130343220311096167
  14. van der Vlugt M, Grobbee EJ, Bossuyt PMM, Bos A, Bongers E, Spijker W, et al. Interval colorectal cancer incidence among subjects undergoing multiple rounds of fecal immunochemical testing. Gastroenterology 2017;153:439–47.e2. 10.1053/j.gastro.2017.05.00428483499
  15. Gill MD, Bramble MG, Rees CJ, Lee TJ, Bradburn DM, Mills SJ. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme. Br J Cancer 2012;107:417–21. 10.1038/bjc.2012.30522782347
  16. Robertson DJ, Greenberg ER, Beach M, Sandler RS, Ahnen D, Haile RW, et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 2005;129:34–41. 10.1053/j.gastro.2005.05.01216012932
  17. Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298–306. 10.1056/NEJMoa130908624693890
  18. Public Health England. Routes to Diagnosis 2015 Update: Colorectal Cancer. London: Public Health England; 2016. URL: www.ncin.org.uk/publications/routes_to_diagnosis (accessed 6 June 2019).
  19. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017;17:79–92. 10.1038/nrc.2016.12628050011
  20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67. 10.1016/0092-8674(90)90186-I2188735
  21. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365–85. 10.3390/ijms14081636523965959
  22. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350–6. 10.1038/nm.396726457759
  23. Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Canc Netw 2017;15:411–19. 10.6004/jnccn.2017.003828275039
  24. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;101:385–98. 10.1111/j.1572-0241.2006.00375.x16454848
  25. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2014;147:502–26. 10.1053/j.gastro.2014.04.00125043945
  26. Roger L, Jones RE, Heppel NH, Williams GT, Sampson JR, Baird DM. Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. J Natl Cancer Inst 2013;105:1202–11. 10.1093/jnci/djt19123918447
  27. East JE, Vieth M, Rex DK. Serrated lesions in colorectal cancer screening: detection, resection, pathology and surveillance. Gut 2015;64:991–1000. 10.1136/gutjnl-2014-30904125748647
  28. World Health Organization (WHO), International Agency for Research on Cancer (IARC). Tumours of the Colon and Rectum. In Bosman FT, Carnerio F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon: IARC; 2010. pp. 160–5.
  29. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847–54. 10.1136/gutjnl-2011-30086522427238
  30. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666–89. 10.1136/gut.2009.17980420427401
  31. Hassan C, Quintero E, Dumonceau JM, Regula J, Brandão C, Chaussade S, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2013;45:842–51. 10.1055/s-0033-134454824030244
  32. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844–57. 10.1053/j.gastro.2012.06.00122763141
  33. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006;130:1872–85. 10.1053/j.gastro.2006.03.01216697750
  34. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008;134:1224–37. 10.1053/j.gastro.2008.02.01218395100
  35. Dulai PS, Singh S, Marquez E, Khera R, Prokop LJ, Limburg PJ, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ 2016;355:i6188. 10.1136/bmj.i618827919915
  36. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015;148:1244–60.e16. 10.1053/j.gastro.2014.12.03525575572
  37. Lynch PM. Chemoprevention of familial adenomatous polyposis. Fam Cancer 2016;15:467–75. 10.1007/s10689-016-9901-927083160
  38. Lee TJ, Rutter MD, Blanks RG, Moss SM, Goddard AF, Chilton A, et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut 2012;61:1050–7. 10.1136/gutjnl-2011-30065121940723
  39. Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016;17:475–83. 10.1016/S1470-2045(15)00565-326947328
  40. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658–62. 10.1056/NEJM1992030532610021736104
  41. Cottet V, Jooste V, Fournel I, Bouvier AM, Faivre J, Bonithon-Kopp C. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut 2012;61:1180–6. 10.1136/gutjnl-2011-30029522110052
  42. Løberg M, Kalager M, Holme Ø, Hoff G, Adami HO, Brett Hauer M. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med 2014;371:799–807. 10.1056/NEJMoa131587025162886
  43. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501–7. 10.1016/S1470-2045(09)70035-X19410194
  44. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016;16:173–86. 10.1038/nrc.2016.426868177
  45. Patrignani P, Patrono C. Aspirin and cancer. J Am Coll Cardiol 2016;68:967–76. 10.1016/j.jacc.2016.05.08327561771
  46. Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603–13. 10.1016/S0140-6736(07)60747-817499602
  47. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741–50. 10.1016/S0140-6736(10)61543-720970847
  48. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77–85. 10.7326/0003-4819-159-2-201307160-0000223856681
  49. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256–66. 10.1093/jnci/djn48519211452
  50. Beck SL. Effects of aspirin on colorectal cancer related to Lynch syndrome. J Adv Pract Oncol 2012;3:395–8. 10.6004/jadpro.2012.3.6.625031971
  51. Burn J, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008;359:2567–78. 10.1056/NEJMoa080129719073976
  52. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:836–45. 10.7326/M16-057727064677
  53. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015;26:47–57. 10.1093/annonc/mdu22525096604
  54. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29:781–8. 10.1038/onc.2009.42119946329
  55. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–52. 10.1056/NEJM20000629342260310874062
  56. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50:470–9. 10.1097/FJC.0b013e318157f72d18030055
  57. Smith WL. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 2005;17:174–82. 10.1016/j.ceb.2005.02.00515780594
  58. Al-Hilal M, Alsaleh A, Maniou Z, Lewis FJ, Hall WL, Sanders TA, O’Dell SD, MARINA study team. Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. J Lipid Res 2013;54:542–51. 10.1194/jlr.P03227623160180
  59. Burdge GC, Calder PC. Dietary alpha-linolenic acid and health-related outcomes: a metabolic perspective. Nutr Res Rev 2006;19:26–52. 10.1079/NRR200511319079874
  60. Hull MA. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer 2005;41:1854–63. 10.1016/j.ejca.2005.04.01316002278
  61. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 2012;61:135–49. 10.1136/gut.2010.23371821490374
  62. MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, Suttorp MJ, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 2006;295:403–15. 10.1001/jama.295.4.40316434631
  63. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med 2016;176:473–82. 10.1001/jamainternmed.2015.858126998708
  64. Kantor ED, Lampe JW, Peters U, Vaughan TL, White E. Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. Nutr Cancer 2014;66:716–27. 10.1080/01635581.2013.80410124053119
  65. Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins, Leukot Essent Fatty Acids 2013;89:1–8. 10.1016/j.plefa.2013.03.01023676322
  66. Ghasemifard S, Turchini GM, Sinclair AJ. Omega-3 long chain fatty acid ‘bioavailability’: a review of evidence and methodological considerations. Prog Lipid Res 2014;56:92–108. 10.1016/j.plipres.2014.09.00125218856
  67. West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010;59:918–25. 10.1136/gut.2009.20064220348368
  68. Fini L, Piazzi G, Ceccarelli C, Daoud Y, Belluzzi A, Munarini A, et al. Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice. Clin Cancer Res 2010;16:5703–11. 10.1158/1078-0432.CCR-10-199021030497
  69. Petrik MB, McEntee MF, Chiu CH, Whelan J. Antagonism of arachidonic acid is linked to the antitumorigenic effect of dietary eicosapentaenoic acid in Apc(Min/+) mice. J Nutr 2000;130:1153–8. 10.1093/jn/130.5.115310801912
  70. Courtney ED, Matthews S, Finlayson C, Di Pierro D, Belluzzi A, Roda E, et al. Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Colorectal Dis 2007;22:765–76. 10.1007/s00384-006-0240-417216221
  71. West N, Belluzzi A, Lund E, al e. Eicosapentaenoic acid (EPA), as the free fatty acid, reduces colonic crypt cell proliferation in patients with sporadic colorectal polyps [abstract]. Gut 2009;58:A68.
  72. Murff HJ, Shrubsole MJ, Cai Q, Smalley WE, Dai Q, Milne GL, et al. Dietary intake of PUFAs and colorectal polyp risk. Am J Clin Nutr 2012;95:703–12. 10.3945/ajcn.111.02400022277551
  73. Higurashi T, Hosono K, Endo H, Takahashi H, Iida H, Uchiyama T, et al. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial. BMC Cancer 2012;12:413. 10.1186/1471-2407-12-41322992267
  74. Hawcroft G, Loadman PM, Belluzzi A, Hull MA. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Neoplasia 2010;12:618–27. 10.1593/neo.1038820689756
  75. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008;3:279–312. 10.1146/annurev.pathmechdis.3.121806.15140918233953
  76. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005;201:713–22. 10.1084/jem.2004203115753205
  77. Kasuga K, Suga T, Mano N. Bioanalytical insights into mediator lipidomics. J Pharm Biomed Anal 2015;113:151–62. 10.1016/j.jpba.2015.02.01125769667
  78. Nabavi SF, Bilotto S, Russo GL, Orhan IE, Habtemariam S, Daglia M, et al. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. Cancer Metastasis Rev 2015;34:359–80. 10.1007/s10555-015-9572-226227583
  79. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585–94. 10.1016/j.jacc.2009.02.08419660687
  80. Larson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, Harris WS. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008;100:634–41. 10.1160/TH08-02-008418841286
  81. Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet 1981;2:1190–3. 10.1016/S0140-6736(81)91436-76118628
  82. Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007;298:1412–19. 10.1001/jama.298.12.141217895457
  83. Benamouzig R, Uzzan B, Martin A, Deyra J, Little J, Girard B, Chaussade S, APACC Study Group. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut 2010;59:622–9. 10.1136/gut.2008.17540620427397
  84. Fekete K, Marosvölgyi T, Jakobik V, Decsi T. Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans: a systematic review. Am J Clin Nutr 2009;89:2070S–2084S. 10.3945/ajcn.2009.27230I19420097
  85. Roy S, Brasky TM, Belury MA, Krishnan S, Cole RM, Marian C, et al. Associations of erythrocyte ω-3 fatty acids with biomarkers of ω-3 fatty acids and inflammation in breast tissue. Int J Cancer 2015;137:2934–46. 10.1002/ijc.2967526137879
  86. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997;38:2012–22.9374124
  87. Cockbain AJ, Volpato M, Race AD, Munarini A, Fazio C, Belluzzi A, et al. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut 2014;63:1760–8. 10.1136/gutjnl-2013-30644524470281
  88. Watson H, Cockbain AJ, Spencer J, Race A, Volpato M, Loadman PM, et al. Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases. Prostaglandins Leukot Essent Fatty Acids 2016;115:60–6. 10.1016/j.plefa.2016.10.00327914515
  89. Volpato M, Spencer JA, Race AD, Munarini A, Belluzzi A, Cockbain AJ, et al. A liquid chromatography-tandem mass spectrometry method to measure fatty acids in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1055–6:125–34. 10.1016/j.jchromb.2017.04.030
  90. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602–12. 10.1016/S0140-6736(11)61720-022440946
  91. Bailey RL, Denby N, Haycock B, Sherif K, Steinbaum S, von Schacky C. Perceptions of a healthy diet: insights from a 3-country survey. Nutr Today 2015;50:282–7. 10.1097/NT.000000000000011926663954
  92. Cao Y, Lu L, Liang J, Liu M, Li X, Sun R, et al. Omega-3 fatty acids and primary and secondary prevention of cardiovascular disease. Cell Biochem Biophys 2015;72:77–81. 10.1007/s12013-014-0407-525427890
  93. Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, Boyer B, Mohatt GV. Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup’ik Eskimos. Am J Clin Nutr 2010;91:777–85. 10.3945/ajcn.2009.2882020089728
  94. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol 2007;99:44C–46C. 10.1016/j.amjcard.2006.11.021
  95. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C, English Bowel Cancer Screening Evaluation Committee. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2012;61:1439–46. 10.1136/gutjnl-2011-30084322156981
  96. Loughrey MB, Shepherd NA. The pathology of bowel cancer screening. Histopathology 2015;66:66–77. 10.1111/his.1253025123305
  97. NHS Cancer Screening Programmes. Reporting Lesions in the NHS Bowel Cancer Screening Programme Guidelines from the Bowel Cancer Screening Programme Pathology Group. London; 2007. URL: www.bcsp.nhs.uk/files/NHS%20BCSP%20Publication%201.pdf (accessed 6 June 2019).
  98. Lee TJ, Nickerson C, Goddard AF, Rees CJ, McNally RJ, Rutter MD. Outcome of 12-month surveillance colonoscopy in high-risk patients in the National Health Service Bowel Cancer Screening Programme. Colorectal Dis 2013;15:e435–42. 10.1111/codi.1227823663559
  99. McGregor LM, Bonello B, Kerrison RS, Nickerson C, Baio G, Berkman L, et al. Uptake of bowel scope (flexible sigmoidoscopy) screening in the English national programme: the first 14 months. J Med Screen 2016;23:77–82. 10.1177/096914131560465926387824
  100. Hull MA, Sandell AC, Montgomery AA, Logan RF, Clifford GM, Rees CJ, et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials 2013;14:237. 10.1186/1745-6215-14-23723895505
  101. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999;354:447–55. 10.1016/S0140-6736(99)07072-510465168
  102. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98:71i–76i. 10.1016/j.amjcard.2005.12.029
  103. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99:35C–43C. 10.1016/j.amjcard.2006.11.020
  104. Covington MB. Omega-3 fatty acids. Am Fam Physician 2004;70:133–40.15259529
  105. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747–57. 10.1161/01.CIR.0000038493.65177.9412438303
  106. Great Britain. The Medicines for Human Use (Clinical Trials) Regulations 2004. London: The Stationery Office; 2004.
  107. Great Britain. Human Tissue Act 2004. London: The Stationery Office; 2004.
  108. McKeown NM, Day NE, Welch AA, Runswick SA, Luben RN, Mulligan AA, et al. Use of biological markers to validate self-reported dietary intake in a random sample of the European Prospective Investigation into Cancer United Kingdom Norfolk cohort. Am J Clin Nutr 2001;74:188–96. 10.1093/ajcn/74.2.18811470719
  109. Scientific Advisory Committee on Nutrition/Committee on Toxicity. Advice on Fish Consumption: Benefits & Risks. 2004. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/338801/SACN_Advice_on_Fish_Consumption.pdf (accessed 31 August 2017).
  110. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol 2003;3:26. 10.1186/1471-2288-3-2614633287
  111. Shrier I, Steele RJ, Verhagen E, Herbert R, Riddell CA, Kaufman JS. Beyond intention to treat: what is the right question? Clin Trials 2014;11:28–37. 10.1177/174077451350415124096636
  112. White IR. Uses and limitations of randomization-based efficacy estimators. Stat Methods Med Res 2005;14:327–47. 10.1191/0962280205sm406oa16178136
  113. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999;231:3–8.10565617
  114. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–9. 10.1056/NEJMoa02173512621133
  115. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328–36. 10.1016/S0016-5085(03)00887-412891533
  116. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313–16. 10.1056/NEJM1993050632818058385741
  117. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29–38. 10.1053/j.gastro.2007.10.01418022173
  118. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883–90. 10.1056/NEJMoa02163312621132
  119. Benamouzig R, Uzzan B, Deyra J, Martin A, Girard B, Little J, Chaussade S, Association pour la Prévention par l’Aspirine du Cancer Colorectal Study Group (APACC). Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut 2012;61:255–61. 10.1136/gutjnl-2011-30011321890814
  120. Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst 2017;109. 10.1093/jnci/djw332
  121. Wallace K, Grau MV, Ahnen D, Snover DC, Robertson DJ, Mahnke D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev 2009;18:2310–7. 10.1158/1055-9965.epi-09-021119661090
  122. Bailie L, Loughrey MB, Coleman HG. Lifestyle risk factors for serrated colorectal polyps: a systematic review and meta-analysis. Gastroenterology 2017;152:92–104. 10.1053/j.gastro.2016.09.00327639804
  123. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res 2011;4:655–65. 10.1158/1940-6207.CAPR-11-0106
  124. Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med 2013;2:50–6. 10.1002/cam4.4624133627
  125. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674–82. 10.1053/j.gastro.2006.08.07917087947
  126. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330. 10.1038/nature1125222810696
  127. Jiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, et al. Biomarkers for personalizing omega-3 fatty acid dosing. Cancer Prev Res 2014;7:1011–22. 10.1158/1940-6207.CAPR-14-0134
  128. Tokudome S, Kuriki K, Yokoyama Y, Sasaki M, Joh T, Kamiya T, et al. Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. Prostaglandins Leukot Essent Fatty Acids 2015;94:1–11. 10.1016/j.plefa.2014.09.00125451556
  129. Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut 2018;67:1974–83. 10.1136/gutjnl-2017-31496828951525
  130. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987;28:1221–7. 10.1136/gut.28.10.12213678950
  131. Kaji I, Karaki S, Tanaka R, Kuwahara A. Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J Mol Histol 2011;42:27–38. 10.1007/s10735-010-9304-421113792
  132. Pan P, Skaer CW, Wang HT, Oshima K, Huang YW, Yu J, et al. Loss of free fatty acid receptor 2 enhances colonic adenoma development and reduces the chemopreventive effects of black raspberries in ApcMin/+ mice. Carcinogenesis 2017;38:86–93. 10.1093/carcin/bgw12227866157
  133. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000;156:545–53. 10.1016/S0002-9440(10)64759-110666384
  134. Nasir A, Lopez A, Boulware D, Malafa M, Coppola D. Correlation between COX-2 and APC expression in left versus right-sided human colon cancer. Anticancer Res 2011;31:2191–5.21737640
  135. Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 2015;162:1257–70. 10.1016/j.cell.2015.08.01526343581
  136. Roseweir AK, McMillan DC, Horgan PG, Edwards J. Colorectal cancer subtypes: translation to routine clinical pathology. Cancer Treat Rev 2017;57:1–7. 10.1016/j.ctrv.2017.04.00628505475
  137. Bensen S, Mott LA, Dain B, Rothstein R, Baron J. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group. Am J Gastroenterol 1999;94:194–9. 10.1111/j.1572-0241.1999.00796.x9934755
  138. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343–50. 10.1111/j.1572-0241.2006.00390.x16454841
  139. Martínez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009;136:832–41. 10.1053/j.gastro.2008.12.00719171141
  140. Keum N, Lee DH, Kim R, Greenwood DC, Giovannucci EL. Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studies. Ann Oncol 2015;26:1101–9. 10.1093/annonc/mdu56325480876
  141. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, et al. A trial of calcium and vitamin D for the prevention of colorectal adenomas. N Engl J Med 2015;373:1519–30. 10.1056/NEJMoa150040926465985
  142. World Health Organization (WHO). Obesity and Overweight. Fact Sheet. 2017. Geneva: WHO; 2017. URL: www.who.int/mediacentre/factsheets/fs311/en/ (accessed 22 December 2017).
  143. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149–55. 10.1056/NEJM20000420342160110770979
  144. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care 2016;25:46–52.26882630
  145. Anti M, Armelao F, Marra G, Percesepe A, Bartoli GM, Palozza P, et al. Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology 1994;107:1709–18. 10.1016/0016-5085(94)90811-77958682
  146. Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 2017;135:e867–84. 10.1161/CIR.000000000000048228289069
  147. Stark KD, Van Elswyk ME, Higgins MR, Weatherford CA, Salem N. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Prog Lipid Res 2016;63:132–52. 10.1016/j.plipres.2016.05.00127216485
  148. Harris WS, Thomas RM. Biological variability of blood omega-3 biomarkers. Clin Biochem 2010;43:338–40. 10.1016/j.clinbiochem.2009.08.01619733159
  149. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME* study. Hepatology 2014;60:1211–21. 10.1002/hep.2728925043514
  150. Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric 2015;95:1260–7. 10.1002/jsfa.681625044306
  151. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the Use of Complementary Health Approaches among Adults: United States, 2002–2012. National health statistics reports; no. 79. Hyattsville, MD: National Center for Health Statistics; 2015. URL: www.cdc.gov/nchs/data/nhsr/nhsr079.pdf (accessed 22 December 2017).
  152. Li L, Geraghty OC, Mehta Z, Rothwell PM, Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017;390:490–9. 10.1016/S0140-6736(17)30770-528622955
  153. Potter JD. The failure of cancer chemoprevention. Carcinogenesis 2014;35:974–82. 10.1093/carcin/bgu06324618374
  154. East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut 2017;66:1181–96. 10.1136/gutjnl-2017-31400528450390
  155. Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, et al. Expression of COX-2 and 15-PGDH in adenomas removed during pretreatment colonoscopy to predict chemopreventive efficacy of the selective COX-2 inhibitor, celecoxib. J Clin Oncol 2017;35:524. 10.1200/JCO.2017.35.4_suppl.524
  156. Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. AM Heart J 2018;198:135–44. 10.1016/j.ahj.2017.12.00629653635
  157. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33:159–71. 10.1016/j.cct.2011.09.00921986389
  158. Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, et al. Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies. Mol Cancer 2017;16:116. 10.1186/s12943-017-0691-y28683746
  159. Wang Y, Sedimbi S, Löfbom L, Singh AK, Porcelli SA, Cardell SL. Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells. Mucosal Immunol 2018;11:131–43. 10.1038/mi.2017.3428401935
  160. Miccadei S, Masella R, Mileo AM, Gessani S. ω3 polyunsaturated fatty acids as immunomodulators in colorectal cancer: new potential role in adjuvant therapies. Front Immunol 2016;7:486. 10.3389/fimmu.2016.0048627895640
  161. Simopoulos AP. Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Exp Biol Med 2010;235:785–95. 10.1258/ebm.2010.009298
← ConclusionsAcknowledgements →

Attribution. Mark A Hull; Kirsty Sprange; Trish Hepburn; Wei Tan; Aisha Shafayat; Colin J Rees et al. (2019). Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2019. This work was produced by Hull et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK543177. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support